Dr. Gauthier on Potential for CAR T Cells in CLL

Video

Jordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses the potential for chimeric antigen receptor T-cell therapy in the treatment of chronic lymphocytic leukemia.

Jordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses the potential for chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with chronic lymphocytic leukemia (CLL).

At the 2018 ASH Annual Meeting, Gauthier presented a study comparing the efficacy and toxicity of the CD19-directed CAR T-cell therapy JCAR014 alone and in combination with the BTK inhibitor ibrutinib (Imbruvica). CAR T cells have demonstrated promise in acute lymphoblastic leukemia and non—Hodgkin lymphoma, Gauthier says, but this type of treatment has not made much headway in CLL. However, recent data have suggested that patients who have relapsed on ibrutinib can achieve deep and durable responses with JCAR014.

Preclinical data suggested that this CAR T cell product in combination with ibrutinib can be beneficial. Gauthier says this could be due to the fact that treatment with ibrutinib in these patients is usually discontinued before CAR T-cell therapy, resulting in a “tumor flare.” Continuing ibrutinib into the infusion of JCAR014 could help overcome this.

Related Videos
Saad J. Kenderian, MB, CHB
Jennifer Brown, MD, PhD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology